The Iraqi Board for Medical Specializations
  • Register
  • Login

Iraqi Postgraduate Medical Journal

Notice

As part of Open Journals’ initiatives, we create website for scholarly open access journals. If you are responsible for this journal and would like to know more about how to use the editorial system, please visit our website at https://ejournalplus.com or
send us an email to info@ejournalplus.com

We will contact you soon

  1. Home
  2. Volume 21, Issue 2
  3. Author

Current Issue

By Issue

By Subject

Keyword Index

Author Index

Indexing Databases XML

About Journal

Aims and Scope

Editorial Board

Advisory Board

Editorial Staff

Publication Ethics

Indexing and Abstracting

News

New Approaches for Diffuse Large B cell Non Hodgkin Lymphoma Management Strategy

    Waseem F. Al Tameemi

Iraqi Postgraduate Medical Journal, 2022, Volume 21, Issue 2, Pages 131-133
10.52573/ipmj.2021.174604

  • Show Article
  • References
  • Download
  • Cite
  • Statistics
  • Share

Abstract

  Diffuse large B cell Non Hodgkin lymphoma (DLBCL) is the most frequent subtype, accounts for 30%–40% of cases. The disease is usually aggressive but there is high chance of cure with appropriate treatment lines.
Keywords:
  • PDF (136 K)
  • XML
(2021). New Approaches for Diffuse Large B cell Non Hodgkin Lymphoma Management Strategy. Iraqi Postgraduate Medical Journal, 21(2), 131-133. doi: 10.52573/ipmj.2021.174604
Waseem F. Al Tameemi. "New Approaches for Diffuse Large B cell Non Hodgkin Lymphoma Management Strategy". Iraqi Postgraduate Medical Journal, 21, 2, 2021, 131-133. doi: 10.52573/ipmj.2021.174604
(2021). 'New Approaches for Diffuse Large B cell Non Hodgkin Lymphoma Management Strategy', Iraqi Postgraduate Medical Journal, 21(2), pp. 131-133. doi: 10.52573/ipmj.2021.174604
New Approaches for Diffuse Large B cell Non Hodgkin Lymphoma Management Strategy. Iraqi Postgraduate Medical Journal, 2021; 21(2): 131-133. doi: 10.52573/ipmj.2021.174604
  • RIS
  • EndNote
  • BibTeX
  • APA
  • MLA
  • Harvard
  • Vancouver

  1. The Non-Hodgkin’s Lymphoma Classification Project NHLCP .A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma. Blood. 1997; 89:3909-3918. https://doi.org/10.1182/blood.V89.11.3909
  2. Ott. German. Aggressive B-cell lymphomas in the update of the 4th edition of the World Health Organization classification of haematopoietic and lymphatic tissues: refinements of the classification, new entities and genetic findings. British Journal of Haematology, 2017, 178, 871–87. doi: 10.1111/bjh.14744.
  3. Philip Th, Guglielmi C, Hagenbeek A, Somers R, Der Lelie HV, Bron D, et al. Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin's Lymphoma. N Engl J Med 1995; 333:1540-1545. doi: 10.1056/NEJM199512073332305
  4. Gisselbrecht C, Glass B, Mounier N, Gill DS, Linch DC, et al. Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era. Journal of Clinical Oncology 2010 28:27, 4184-4190. DOI: 10.1200/JCO.2010.28.1618
  5. Adaniya  SS and Barta SK. 2021 Update on Diffuse large B cell lymphoma: A review of current dataand potential applications on risk stratification and management. Am J Hematol. 2021 :1;96:617–29.
  6.  Johnson NA, Slack GW, Savage KJ, Connors JM, Ben-Neriah S, Rogic S, et al. Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. Journal of Clinical Oncology 2012 30:28, 3452-3459. DOI: 10.1200/JCO.2011.41.0985
  7. Rosenwald A, Bens S, Advani R, Barrans S, Copie-Bergman C, Elsensohn MH,et al. Prognostic Significance of MYC Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium.Journal of Clinical Oncology 2019 37:35, 3359-3368. DOI: 10.1200/JCO.19.00743.
  8. Tilly H, Morschhauser F , Bartlett NL, Mehta A , Salles G , Haioun C et al. Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b–2 study. Lancet Oncol. 2019;20:998.DOI:https://doi.org/10.1016/S1470-2045(19)30091-9
  9. Neelapu SS, Locke FL, Bartlett NL, Lekakis L J, Miklos DB, Jacobson CA, Braunschweig I, et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med 2017;377:2531-44. DOI: 10.1056/NEJMoa1707447

10. Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med 2019; 380:45-56. DOI: 10.1056/NEJMoa1804980

11. Salles G, Duell  J, Barca EG , Tournilhac O, W, Liberati AM, et al.Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol. 2020;21:978. https://doi.org/10.1016/S1470-2045(20)30225-4

12. Maerevoet M, Zijlstra JM, Follows G, et al. Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study. J Hematol Oncol. 2021;14(1):111. Published 2021 Jul 16. doi:10.1186/s13045-021-01122-1

13. Hutchings M, Offner FC, Bosch F, Gritti G, Carlo-Stella C, Walter H, et al. Phase 1 Study of CD19 Targeted 4-1BBL Costimulatory Agonist to Enhance T Cell (Glofitamab Combination) or NK Cell Effector Function (Obinutuzumab Combination) in Relapsed/Refractory B Cell Lymphoma. Blood2020 ; 136, Supplement 1,16-17. https://doi.org/10.1182/blood-2020-136571.

  • Article View: 68
  • PDF Download: 27
  • LinkedIn
  • Twitter
  • Facebook
  • Google
  • Telegram
  • Home
  • Glossary
  • News
  • Aims and Scope
  • Privacy Policy
  • Sitemap
This journal is licensed under a Creative Commons Attribution 4.0 International (CC-BY 4.0)

Powered by eJournalPlus